![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SPINT2 |
Gene summary for SPINT2 |
![]() |
Gene information | Species | Human | Gene symbol | SPINT2 | Gene ID | 10653 |
Gene name | serine peptidase inhibitor, Kunitz type 2 | |
Gene Alias | DIAR3 | |
Cytomap | 19q13.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A140VJV6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10653 | SPINT2 | GSM4909280 | Human | Breast | Precancer | 3.84e-03 | -6.73e-01 | 0.0305 |
10653 | SPINT2 | GSM4909281 | Human | Breast | IDC | 2.26e-09 | 3.08e-01 | 0.21 |
10653 | SPINT2 | GSM4909282 | Human | Breast | IDC | 2.28e-12 | 3.11e-01 | -0.0288 |
10653 | SPINT2 | GSM4909285 | Human | Breast | IDC | 4.84e-44 | 5.52e-01 | 0.21 |
10653 | SPINT2 | GSM4909286 | Human | Breast | IDC | 5.38e-08 | -1.41e-01 | 0.1081 |
10653 | SPINT2 | GSM4909291 | Human | Breast | IDC | 5.32e-14 | 4.24e-01 | 0.1753 |
10653 | SPINT2 | GSM4909293 | Human | Breast | IDC | 1.81e-04 | 2.62e-01 | 0.1581 |
10653 | SPINT2 | GSM4909294 | Human | Breast | IDC | 1.52e-14 | -2.81e-01 | 0.2022 |
10653 | SPINT2 | GSM4909296 | Human | Breast | IDC | 6.23e-07 | -1.80e-01 | 0.1524 |
10653 | SPINT2 | GSM4909297 | Human | Breast | IDC | 4.98e-16 | -1.57e-01 | 0.1517 |
10653 | SPINT2 | GSM4909298 | Human | Breast | IDC | 6.17e-06 | 2.40e-01 | 0.1551 |
10653 | SPINT2 | GSM4909305 | Human | Breast | IDC | 9.67e-03 | 2.45e-01 | 0.0436 |
10653 | SPINT2 | GSM4909306 | Human | Breast | IDC | 8.91e-56 | 6.21e-01 | 0.1564 |
10653 | SPINT2 | GSM4909307 | Human | Breast | IDC | 1.27e-03 | 2.30e-01 | 0.1569 |
10653 | SPINT2 | GSM4909309 | Human | Breast | IDC | 1.28e-02 | 1.45e-02 | 0.0483 |
10653 | SPINT2 | GSM4909311 | Human | Breast | IDC | 3.22e-37 | -1.93e-01 | 0.1534 |
10653 | SPINT2 | GSM4909312 | Human | Breast | IDC | 1.27e-10 | 1.88e-01 | 0.1552 |
10653 | SPINT2 | GSM4909313 | Human | Breast | IDC | 1.56e-02 | 1.34e-01 | 0.0391 |
10653 | SPINT2 | GSM4909315 | Human | Breast | IDC | 1.66e-09 | 3.63e-02 | 0.21 |
10653 | SPINT2 | GSM4909316 | Human | Breast | IDC | 1.62e-05 | -1.02e-01 | 0.21 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:20001783 | Oral cavity | NEOLP | negative regulation of neural precursor cell proliferation | 7/2005 | 21/18723 | 4.79e-03 | 2.62e-02 | 7 |
GO:007177212 | Oral cavity | NEOLP | response to BMP | 29/2005 | 165/18723 | 5.04e-03 | 2.73e-02 | 29 |
GO:007177312 | Oral cavity | NEOLP | cellular response to BMP stimulus | 29/2005 | 165/18723 | 5.04e-03 | 2.73e-02 | 29 |
GO:002240822 | Oral cavity | NEOLP | negative regulation of cell-cell adhesion | 33/2005 | 196/18723 | 5.76e-03 | 3.04e-02 | 33 |
GO:006067012 | Oral cavity | NEOLP | branching involved in labyrinthine layer morphogenesis | 5/2005 | 13/18723 | 8.62e-03 | 4.15e-02 | 5 |
GO:006056215 | Oral cavity | NEOLP | epithelial tube morphogenesis | 49/2005 | 325/18723 | 8.68e-03 | 4.17e-02 | 49 |
GO:000206417 | Prostate | BPH | epithelial cell development | 85/3107 | 220/18723 | 3.16e-15 | 4.55e-13 | 85 |
GO:006145810 | Prostate | BPH | reproductive system development | 126/3107 | 427/18723 | 1.35e-11 | 9.95e-10 | 126 |
GO:005254718 | Prostate | BPH | regulation of peptidase activity | 133/3107 | 461/18723 | 2.08e-11 | 1.43e-09 | 133 |
GO:004860810 | Prostate | BPH | reproductive structure development | 124/3107 | 424/18723 | 3.76e-11 | 2.43e-09 | 124 |
GO:000716316 | Prostate | BPH | establishment or maintenance of cell polarity | 75/3107 | 218/18723 | 9.93e-11 | 5.97e-09 | 75 |
GO:005254818 | Prostate | BPH | regulation of endopeptidase activity | 122/3107 | 432/18723 | 6.10e-10 | 2.91e-08 | 122 |
GO:000170110 | Prostate | BPH | in utero embryonic development | 104/3107 | 367/18723 | 9.17e-09 | 3.10e-07 | 104 |
GO:004586118 | Prostate | BPH | negative regulation of proteolysis | 98/3107 | 351/18723 | 5.43e-08 | 1.49e-06 | 98 |
GO:000189010 | Prostate | BPH | placenta development | 50/3107 | 144/18723 | 8.97e-08 | 2.20e-06 | 50 |
GO:00017638 | Prostate | BPH | morphogenesis of a branching structure | 61/3107 | 196/18723 | 3.33e-07 | 7.06e-06 | 61 |
GO:000189210 | Prostate | BPH | embryonic placenta development | 32/3107 | 82/18723 | 9.93e-07 | 1.80e-05 | 32 |
GO:00611385 | Prostate | BPH | morphogenesis of a branching epithelium | 56/3107 | 182/18723 | 1.48e-06 | 2.56e-05 | 56 |
GO:00605628 | Prostate | BPH | epithelial tube morphogenesis | 87/3107 | 325/18723 | 2.05e-06 | 3.39e-05 | 87 |
GO:00071628 | Prostate | BPH | negative regulation of cell adhesion | 82/3107 | 303/18723 | 2.51e-06 | 4.04e-05 | 82 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPINT2 | SNV | Missense_Mutation | novel | c.367T>A | p.Ser123Thr | p.S123T | O43291 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
SPINT2 | SNV | Missense_Mutation | c.68N>G | p.Ser23Cys | p.S23C | O43291 | protein_coding | tolerated_low_confidence(0.06) | benign(0) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SPINT2 | SNV | Missense_Mutation | rs11548458 | c.142N>T | p.Arg48Trp | p.R48W | O43291 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPINT2 | SNV | Missense_Mutation | c.443N>A | p.Arg148His | p.R148H | O43291 | protein_coding | deleterious(0) | possibly_damaging(0.709) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
SPINT2 | SNV | Missense_Mutation | c.510N>T | p.Lys170Asn | p.K170N | O43291 | protein_coding | deleterious(0) | possibly_damaging(0.74) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SPINT2 | deletion | Frame_Shift_Del | c.205delN | p.Gly70AlafsTer10 | p.G70Afs*10 | O43291 | protein_coding | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | |||
SPINT2 | SNV | Missense_Mutation | rs746801741 | c.457G>A | p.Val153Met | p.V153M | O43291 | protein_coding | deleterious(0.05) | possibly_damaging(0.75) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPINT2 | SNV | Missense_Mutation | novel | c.16N>A | p.Gly6Arg | p.G6R | O43291 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.652) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPINT2 | SNV | Missense_Mutation | c.316N>T | p.Ala106Ser | p.A106S | O43291 | protein_coding | tolerated(0.06) | benign(0.074) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SPINT2 | SNV | Missense_Mutation | c.580N>T | p.Leu194Phe | p.L194F | O43291 | protein_coding | tolerated(0.7) | benign(0.04) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |